Document is current
Any future updates will be listed below
-
Authors
Torres, Tiago https://orcid.org/0000-0003-0404-0870
Blauvelt, Andrew
- License Information
-
More Information
Article History
Received: 6 February 2026
Accepted: 20 February 2026
First Online: 3 March 2026
Declarations
:
: Tiago Torres: speaker, scientific adviser, and clinical study investigator for AbbVie, Almirall, Amgen, Apogee, Arena Pharmaceuticals, Biocad, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Johnson and Johnson, LEO Pharma, Eli Lilly, MSD, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, STADA, and UCB. Tiago Torres is an Editorial Board member of Dermatology and Therapy . Tiago Torres was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Andrew Blauvelt: speaker (received honoraria) for Almirall, Eli Lilly, Leo, Sanofi, and UCB, scientific adviser (received honoraria) for AbbVie, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Eli Lilly, Incyte, Janssen, Leo, Novartis, Oruka, Paragon, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB and stock owner in Lipidio and Oruka.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
